Trastuzumab Deruxtecan Alone or in Combination with Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Recruiting

Phase 2

Trastuzumab Deruxtecan Alone or in Combination with Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Sponsor:

Jonsson Comprehensive Cancer Center

Code:

NCT04553770

Conditions

Early-stage Breast Cancer

Hormone Receptor Positive Breast Carcinoma

Invasive Breast Cancer

Stage II Breast Cancer

Stage IIA Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Anastrozole

Therapeutic Conventional Surgery

Trastuzumab Deruxtecan

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by Jonsson Comprehensive Cancer Center on 2024-09-25.